Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate

Bone Marrow Transplantation

Volumn 17, Issue 3, 1996, Pages 443-447

  Patton, D F ^a,b   Harper, J L ^a   Wooldridge, T N ^a   Gordon, B G ^a   Coccia, P ^a   Haire, W D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Antithrombin III; Continuous infusion; Organ dysfunction; Therapy; Ultrasound; Veno occlusive disease

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III CONCENTRATE; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; HEPARIN; MESNA; PREDNISONE; PROCARBAZINE; THIOTEPA; TISSUE PLASMINOGEN ACTIVATOR; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; CASE REPORT; CONTINUOUS INFUSION; FEMALE; HUMAN; LIVER VEIN OBSTRUCTION; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PORTAL VEIN BLOOD FLOW; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK;

ADOLESCENT; ANTITHROMBIN III; BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER; PLASMINOGEN ACTIVATORS; SYNDROME; TISSUE PLASMINOGEN ACTIVATOR; VENOUS INSUFFICIENCY;

EID: 0030002997     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
2. Shulman HM, McDonald GB, Matthews D et al. An analysis of hepatic veno-occlusive and centrilobular hepatic degeneration following bone marrow transplantation. Gastoenterology 1980; 79: 1178-1191.
3. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
4. McDonald GB. Veno-occlusive disease of the liver following marrow transplantation. Marrow Transplant Rev Winter 1993/1994; 3: 49-56.
5. Wingard JR, Melitis ED, Johes RJ et al. Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 685-689.
6. Gordon B, Haire W, Kessinger A et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1991; 8: 497-502.
7. Faioni EM, Krachmaninicoff A, Bearman SI et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of veno-occlusive disease of the liver. Blood 1993; 81: 3458-3462.
8. Scrobohaci ML, Drouet L, Monem-Mansi A et al. Liver venoocclusive disease after bone marrow transplantation. Changes in coagulation parameters and endothelial markers. Thromb Res 1991; 63: 509-519.
9. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-2462.
10. Bearman SI, Hinds MS, Wolford JL et al. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407-411.
11. Pole JG, Casper J, Elfenbein G et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 152-158.
12. Prellwitz W, Schmitt KF, Machner M et al. Two automated methods for plasma antithrombin III compared, and the clinical significance of the results. Clin Chem 1982; 28: 2249-2253.
13. Brown BP, Abu-Yousef M, Famer R et al. Doppler sonography: a noninvasive method for evaluation of hepatic venocclusive disease. Am J Roentgenol 1990; 154: 721-724.
14. Jones PJ, Kamthorn SKL, Beschorner WE et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
15. Haire WD, Ruby EI, Gordon BG et al. Antithrombin III (ATIII) and protein C (PC) deficiencies during hematopoietic stem cell transplantation (HSCT) correlate with organ dysfunction and death. Blood 1993; 82 (Suppl. 1): 406a (abstr. 1609).
16. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III protein C and protein S deficiencies. Chest 1992; 101: 816-823.
17. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemostas 1993; 69: 98-102.
18. Martinowitz U, Schulman S, Gitel S et al. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82: 729-734.
19. Schwartz RS, Bauer KA, Rosenberg RD et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 1989; 87: 53-60.
20. Haire WD, Stephens LC, Kotulak GD et al. Pharmacokinetics of antithrombin concentrate during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 1995; 15: 505-507.